Time for tocilizumab in COVID-19?
| Field | Value | Language |
| dc.contributor.author | Butler E. | en |
| dc.contributor.author | Munch M.W. | en |
| dc.contributor.author | Venkatesh B. | en |
| dc.date.accessioned | 2021-06-25T05:24:53Z | |
| dc.date.available | 2021-06-25T05:24:53Z | |
| dc.date.issued | 2021 | |
| dc.identifier.uri | https://hdl.handle.net/2123/25492 | |
| dc.language.iso | en | en |
| dc.rights | Other | |
| dc.subject | COVID-19 | en |
| dc.subject | Coronavirus | en |
| dc.title | Time for tocilizumab in COVID-19? | en |
| dc.type | Article | en |
| dc.identifier.doi | 10.1007/s00134-021-06441-y | |
| usyd.faculty | Faculty of Medicine and Health, Sydney Medical School | en |
Associated file/s
There are no files associated with this item.
Associated collections